Pilot Randomized Trial With Flecainide in ARVC Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 23, 2019

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Arrhythmogenic Right Ventricular Cardiomyopathy
Interventions
DRUG

Flecainide Pill

Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each

DRUG

Placebo

Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each

Trial Locations (6)

10016

New York University, New York

14642

University of Rochester Medical Center, Rochester

19104

University of Pensylvania, Philadelphia

21287

John Hopkins University, Baltimore

27710

Duke University, Durham

80045

University of Colorado, Denver

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Rochester

OTHER

NCT03685149 - Pilot Randomized Trial With Flecainide in ARVC Patients | Biotech Hunter | Biotech Hunter